The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada

Canadian Journal of Infectious Diseases

Volumn 15, Issue 4, 2004, Pages 213-220

  Rosner, Andrew J ^a   Becker, Debbie L ^a   Wong, Angelina H ^b   Miller, Elizabeth ^b   Conly, John M ^c  

^a i3 Global   (Canada)

^b Patient Access and Outcomes Research   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Consequences; Costs; Linezolid; Methicillin resistant Staphylococcus aureus; MRSA; Vancomycin

Indexed keywords

LINEZOLID; METICILLIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOME CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TEACHING HOSPITAL;

EID: 4644268322     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/383461     Document Type: Article

References (35)

1. World Health Organization. Overcoming Antimicrobial Resistance World Health Report on Infectious Diseases 2000 〈www.who.int/infectious-disease- report/2000/〉 (Version current at July 1, 2004).
2. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417-23.
3. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065-78.
4. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
5. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5.
6. Low DE, Garcia M, Callery S. Methicillin-resistant Staphylococcus aureus - Ontario. Can Dis Wkly Rep 1981;7:249-50.
7. Conly J, Johnston BL. Antibiotic resistance in Canada at the dawn of the new millennium - a model for the developed world? Can J Infect Dis 2000;11:232-5.
8. Conly J. Antimicrobial resistance in Canada. CMAJ 2002;167:885-91.
9. Taylor G, Kirkland T, Kowalewska-Grochowska K, Wang Y. A multistrain cluster of methicillin-resistant Staphylococcus aureus based in a native community. Can J Infect Dis 1990;1:121-6.
10. Embil J, Ramotar K, Romance R, et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol 1994;15:646-51.
11. Berlet G, Richards RS, Roth JH. Clenched-fist injury complicated by methicillin-resistant Staphylococcus aureus. Can J Surg 1997;40:313-4.
12. Gardam MA. Is methicillin-resistant Staphylococcus aureus an emerging community pathogen? A review of the literature. Can J Infect Dis 2000;11:202-11.
13. Kim T, Oh P, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104.
14. Bryce EA, Kerschbaumer V. The cost of doing business - managing MRSA and VRE. 4th Decennial International Conference on Nosocomial and Healthcare-associated Infections. Infect Control Hosp Epidemiol 2000;21:119. (Abst SM5-05)
15. Ford CW, Hamel JC, Stapert D, et al. Oxazolidinones: New antibacterial agents. Trends Microbiol 1997;5:196-200.
16. Devlin HR. Bacteria for the nineties. Ostomy Wound Manage 1998;44:32-40.
17. Rubinstein E, Cammarata SK, Iliphant TH, Wunderink RC. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
18. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy 2001;21:263-74.
19. Dietrich ES, Joseph U, Vogel F, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection 1999;27:148-54.
20. Rittenhouse BE, Stinnett AA, Dulisse B, et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care 2000;6:381-9.
21. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-48.
22. Omidvari K, de Boisblanc BP, Karam C, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: Duration of therapy, clinical outcomes and cost analysis. Respir Med 1998;92:1032-9.
23. Conly JM, Stiver GH, Weiss KA, Becker DL, Rosner AJ, Miller E. A retrospective analysis of practice patterns in the treatment of methicillin-resistant Staphylococcus aureus skin and soft tissue infections at three Canadian tertiary care centers. Can J Infect Dis 2003;14:315-21.
24. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics 1994;5(Suppl 2):20-6.
25. Zamin MT, Monique MP, Conly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother 1997;31:564-70.
26. Sunnybrook and Women's College Health Sciences Centre. Formulary and Drug Use Guidelines. Toronto, 1997.
27. Ontario Ministry of Health and Long-term Care. Ontario Drug Benefit Formulary, Comparative Drug Index No. 37. 2001.
28. Ontario Schedule of Benefits. Physician Services under the Health Insurance Act. 2000.
29. Hamilton-Wentworth District Health Council. Inventory of Long-term Care Services. 2000.
30. Fleming CA, Green K, Richardson H, et al. Evolution of antimicrobial resistance in nosocomial gram positive pathogens in Ontario, Canada. Conjoint Meeting of CACMID, CHICA, & CIDS. 2001:52. (Abst). 〈www.cacmid.ca/ abstracts_01/p52.htm〉 (Version current at July 23, 2004).
31. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BC. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55.
32. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29:561-5.
33. Siegal RE, Halpern NA, Almonoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.
34. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: Four years of experience in a large teaching hospital. Ann Pharmacother 1992;26:1447-51.
35. Paladino JA. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can J Hosp Pharm 1995;48:276-83.